Cystic fibrosis has become the poster child for precision medicine – most new therapies are carefully tailored to a CF patient’s genetic makeup. University of North Carolina spinout Spyryx Biosciences is proposing a one-size-fits-all approach to the disease: It’s developing a peptide-based therapy that, in theory, could be effective among all CF patients. Continue reading UNC spinout looking to one-up Kalydeco with one-size-fits-all cystic fibrosis therapy
Cayston (aztreonam for inhalation solution) Availability 2015
On December 22nd, Gilead sent out a “Dear Healthcare Provider” announcement that they and Cystic Fibrosis Services, Inc. (CFS) Walgreens have mutually agreed that CFS will transition out of the network of pharmacies providing Cayston.
Foundation Care Pharmacy is currently a provider of Cayston (aztreonam for inhalation solution) /Altera nebulizer to CF patients nationwide. They would like the opportunity to assist you in using Cayston.
Foundation Care provides pharmacy services to over 6,000 cystic fibrosis patients nationwide. They have been providing Cayston and support for the Altera device since the product was launched in 2010. They offer full retail pharmacy services and will meet all of your pharmacy needs. Foundation Care will:
Contact CF patients pharmacy, transfer their Cayston prescriptions, perform reimbursement, prior authorization, fulfillment and dispensing services, offer free home delivery of Cayston via Fed Ex next day service, and provide compliance and adherence services to patients, including refill reminders.
In addition, patients receiving Cayston from Foundation Care will also receive at no cost:
• A Nebulizer Cleaning Kit
• Their choice of either: Vitamin D3 (Replesta), Hypertonic Saline or ChoiceFul Vitamins
The Cystic Fibrosis Foundation will sell royalties it gets from Vertex Pharmaceuticals Inc. (VRTX)for $3.3 billion to Royalty Pharma, taking a profit from charitable investments made to fight the fatal lung disease.
Last week marked my 10th anniversary of my bilateral lung transplant. Safe to say, I have beaten the odds once again, and am still around to talk about it. My transplant surgeon, Dr. Bryan Meyers, tells me only 15-20% of patients are still alive at the 10-year mark. Odds are getting better, but it’s a very slow climb in improvements. Continue reading Life, 10 years post transplant
A novel Cystic Fibrosis testing technology that features next-generation DNA sequencing platforms has been launched by Medical Diagnostic Laboratories, L.L.C. Certified by the Clinical Laboratory Improvement Amendments (CLIA) and accredited by the College of American Pathologists (CAP), MDL specializes in complex, state-of-the-art, automated DNA-based molecular analyses. Continue reading MDL Provides New Prenatal Cystic Fibrosis Testing
From an early age, the lungs of individuals with cystic fibrosis (CF) are colonised and infected by bacteria, a common example being S. aureus. These bacterial infections cause the lungs to become inflamed, infected, and can eventually lead to permanent lung damage. Researchers from the University of Pennsylvania and the Howard Hughes Medical Institute previously showed that an enzyme called Sphingomyelin phosphodiesterase C (SMaseC) produced by the S. aureus bacterium may harm the health of CF patients. Now, they have discovered an inhibitor for this pathogenic bacterial enzyme. Continue reading Researchers identify potential drug that could help treat cystic fibrosis
Synedgen, Inc. will present recent study results on the successful application of the company’s novel polymer PAAG for treating Cystic Fibrosis. The data is compiled in two posters entitled “PAAG decreases viscosity and Improves Transportability of Cystic Fibrosis Mucus In Situ” and “Novel Biopolymer Mucolytic PAAG Prevents and Treats Biofilms formed by Cystic Fibrosis Clinical Isolates In Vitro, and Potentiates Tobramycin, Aztreonam, and Vancomycin Activity Against Pseudomonas Aeruginosa and MRSA” which will be presented at the National Cystic Fibrosis Meeting in Atlanta, on October 8-11, 2014. Continue reading Novel Cystic Fibrosis Treatment Shows Promise Against Infections
Cystic fibrosis (CF) patients are particularly susceptible to complications if they acquire a respiratory infection. The live-attenuated influenza vaccine can significantly reduce the risk of infection; however, the question arose as to whether it was safe for CF patients. Therefore, Canadian researchers conducted a study to evaluate the safety of the vaccine in these individuals. They published their findings online on September 15 in the journal Pediatrics. Continue reading Is the influenza vaccine safe for cystic fibrosis patients?
A new study, entitled, “Pseudomonas aeruginosa adaptation in the nasopharyngeal reservoir leads to migration and persistence in the lungs,” conducted at the University of Liverpool’s Institute of Infection and Global Health, UK, published in Nature Communications, and led by the group of the Professors Aras Kadioglu and Craig Winstanley, show for the first time a new reservoir of infection, the nasopharynx, by Pseudomonas aeruginosa that may explain recurrent infections and the development of chronic lung infection in patients with cystic fibrosis (CF). Continue reading Nasopharynx in CF Patients May Be Where Bacterial Infections Hide
MONDAY, Aug. 18, 2014 (HealthDay News) — In the United States, children born in 2010 with cystic fibrosis (CF) are projected to live longer than those born earlier, according to a study published in the Aug. 19 issue of the Annals of Internal Medicine. Continue reading United States Children with Cystic Fibrosis are Living Longer